Guidance for Alnylam Pharmaceuticals, Inc. (ALNY)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $4.90B – 5.30B | $5.55B | = Maintained | Details |
| 2025 | N/A | N/A | $2.05B – 2.25B | $2.68B | = Maintained | Details |
| 2024 | N/A | N/A | $1.40B – 1.50B | $1.85B | = Maintained | Details |
| 2024 | N/A | N/A | $1400.00M – 1500.00M | $1770.00M | = Maintained | Details |
| 2022 | N/A | N/A | $870.00M – 930.00M | $1.00M | = Maintained | Details |
| Q3 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
